120 related articles for article (PubMed ID: 9667929)
21. Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock.
Zingarelli B; Haskó G; Salzman AL; Szabó C
Crit Care Med; 1999 Sep; 27(9):1701-7. PubMed ID: 10507586
[TBL] [Abstract][Full Text] [Related]
22. Exogenous nitric oxide causes potentiation of hippocampal synaptic transmission during low-frequency stimulation via the endogenous nitric oxide-cGMP pathway.
Bon CL; Garthwaite J
Eur J Neurosci; 2001 Aug; 14(4):585-94. PubMed ID: 11556884
[TBL] [Abstract][Full Text] [Related]
23. cGMP-mediated facilitation in nerve terminals by enhancement of the spike afterhyperpolarization.
Klyachko VA; Ahern GP; Jackson MB
Neuron; 2001 Sep; 31(6):1015-25. PubMed ID: 11580900
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide-sensitive guanylyl cyclase inhibits acetylcholine release and excitatory motor transmission in the guinea-pig ileum.
Hebeiss K; Kilbinger H
Neuroscience; 1998 Jan; 82(2):623-9. PubMed ID: 9466466
[TBL] [Abstract][Full Text] [Related]
25. Nitric oxide inhibits spleen cell proliferative response after burn injury by inducing cytostasis, apoptosis, and necrosis of activated T lymphocytes: role of the guanylate cyclase.
Valenti L; Mathieu J; Chancerelle Y; Levacher M; Chanaud B; De Sousa M; Strzalko S; Dinh-Xuan AT; Giroud JP; Florentin I
Cell Immunol; 2003 Jan; 221(1):50-63. PubMed ID: 12742382
[TBL] [Abstract][Full Text] [Related]
26. Topical application of neuronal nitric oxide synthase inhibitor accelerates cutaneous barrier recovery and prevents epidermal hyperplasia induced by barrier disruption.
Ikeyama K; Fuziwara S; Denda M
J Invest Dermatol; 2007 Jul; 127(7):1713-9. PubMed ID: 17363920
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory transmission to the longitudinal muscle of the mouse caecum is mediated largely by nitric oxide acting via soluble guanylyl cyclase.
Young HM; Ciampoli D; Johnson PJ; Stebbing MJ
J Auton Nerv Syst; 1996 Nov; 61(2):103-8. PubMed ID: 8946328
[TBL] [Abstract][Full Text] [Related]
28. cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide.
Vaziri ND; Wang XQ
Hypertension; 1999 Dec; 34(6):1237-41. PubMed ID: 10601124
[TBL] [Abstract][Full Text] [Related]
29. Role of central glutamate receptors, nitric oxide and soluble guanylyl cyclase in the inhibition by endotoxin of rat gastric acid secretion.
García-Zaragozá E; Barrachina MD; Moreno L; Esplugues JV
Br J Pharmacol; 2000 Jul; 130(6):1283-8. PubMed ID: 10903967
[TBL] [Abstract][Full Text] [Related]
30. [Physiological and physiopathological aspects of nitric acid in mammalian tissues].
Molero-Leal M
Invest Clin; 1998 Jun; 39(2):125-54. PubMed ID: 9707923
[TBL] [Abstract][Full Text] [Related]
31. Roles of guanylate cyclase in responses to myogenic and neural nitric oxide in canine lower esophageal sphincter.
Daniel EE; Bowes TJ; Jury J
J Pharmacol Exp Ther; 2002 Jun; 301(3):1111-8. PubMed ID: 12023544
[TBL] [Abstract][Full Text] [Related]
32. Effects of nitric oxide on P2Y receptor resensitization in spontaneously hypertensive rat mesangial cells.
Liu R; Persson AE
J Hypertens; 2002 Sep; 20(9):1835-42. PubMed ID: 12195127
[TBL] [Abstract][Full Text] [Related]
33. Soluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse.
Zhu G; Groneberg D; Sikka G; Hori D; Ranek MJ; Nakamura T; Takimoto E; Paolocci N; Berkowitz DE; Friebe A; Kass DA
Hypertension; 2015 Feb; 65(2):385-92. PubMed ID: 25452469
[TBL] [Abstract][Full Text] [Related]
34. Influence of soluble guanylate cyclase inhibition on inflammation and motility disturbances in DSS-induced colitis.
Van Crombruggen K; Van Nassauw L; Demetter P; Cuvelier C; Timmermans JP; Lefebvre RA
Eur J Pharmacol; 2008 Jan; 579(1-3):337-49. PubMed ID: 18022154
[TBL] [Abstract][Full Text] [Related]
35. Nomega-hydroxy-L-arginine homologues and hydroxylamine as nitric oxide-dependent vasorelaxant agents.
Beranova P; Chalupsky K; Kleschyov AL; Schott C; Boucher JL; Mansuy D; Munzel T; Muller B; Stoclet JC
Eur J Pharmacol; 2005 Jun; 516(3):260-7. PubMed ID: 15964563
[TBL] [Abstract][Full Text] [Related]
36. Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion.
Brunner F; Stessel H; Kukovetz WR
FEBS Lett; 1995 Dec; 376(3):262-6. PubMed ID: 7498555
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect.
Hanke CJ; Drewett JG; Myers CR; Campbell WB
Endocrinology; 1998 Oct; 139(10):4053-60. PubMed ID: 9751482
[TBL] [Abstract][Full Text] [Related]
38. Endothelium-dependent vasorelaxation independent of nitric oxide and K(+) release in isolated renal arteries of rats.
Jiang F; Dusting GJ
Br J Pharmacol; 2001 Apr; 132(7):1558-64. PubMed ID: 11264250
[TBL] [Abstract][Full Text] [Related]
39. Effects of a novel guanylate cyclase inhibitor on nitric oxide-dependent inhibitory neurotransmission in canine proximal colon.
Franck H; Sweeney KM; Sanders KM; Shuttleworth CW
Br J Pharmacol; 1997 Nov; 122(6):1223-9. PubMed ID: 9401790
[TBL] [Abstract][Full Text] [Related]
40. Involvement of nitric oxide-soluble guanylyl cyclase pathway in the control of maximal dentate gyrus activation in the rat.
Sardo P; Carletti F; D'Agostino S; Rizzo V; Ferraro G
J Neural Transm (Vienna); 2006 Dec; 113(12):1855-61. PubMed ID: 16736237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
